About Bifunctional peptidase and arginyl-hydroxylase JMJD5
Bifunctional peptidase and arginyl-hydroxylase JMJD5 (KDM8) is a protein
from Homo sapiens identified by UniProt accession
Q8N371, 416 residues long.
MolForge cross-references it against 0 known binders and
56 disease associations.
Target properties
| Protein name | Bifunctional peptidase and arginyl-hydroxylase JMJD5 |
| UniProt accession | Q8N371 |
| Gene | KDM8 |
| Organism | Homo sapiens |
| Length | 416 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (56)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.44
- breast adenocarcinoma · score 0.22
- Coffin-Siris syndrome · score 0.15
- gut microbiome measurement · score 0.13
- taxonomic microbiome measurement · score 0.13
- acute myeloid leukemia · score 0.12
- hepatocellular carcinoma · score 0.09
- non-small cell lung carcinoma · score 0.09
- Dilated cardiomyopathy · score 0.07
- neoplasm · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N371-F1 | alphafold | PREDICTED | 88.90 | — |
Amino-acid sequence (416 residues)
MAGDTHCPAE PLAREGTLWE ALRALLPHSK EDLKLDLGEK VERSVVTLLQ RATELFYEGR RDECLQSSEV ILDYSWEKLN TGTWQDVDKD WRRVYAIGCL LKALCLCQAP EDANTVAAAL RVCDMGLLMG AAILGDILLK VAAILQTHLP GKRPARGSLP EQPCTKKARA DHGLIPDVKL EKTVPRLHRP SLQHFREQFL VPGRPVILKG VADHWPCMQK WSLEYIQEIA GCRTVPVEVG SRYTDEEWSQ TLMTVNEFIS KYIVNEPRDV GYLAQHQLFD QIPELKQDIS IPDYCSLGDG EEEEITINAW FGPQGTISPL HQDPQQNFLV QVMGRKYIRL YSPQESGALY PHDTHLLHNT SQVDVENPDL EKFPKFAKAP FLSCILSPGE ILFIPVKYWH YVRALDLSFS VSFWWS
Explore Bifunctional peptidase and arginyl-hydroxylase JMJD5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets